Brooks Laboratories Ltd H1 FY2026 – Pharma Comeback with a Side of Comedy and a Merger Hangover

1. At a Glance

Brooks Laboratories Ltd (NSE: BROOKS, BSE: 533543) is that small-cap pharma stock that’s been through more drama than a daily soap. From losing money on its Vadodara unit to turning profitable after giving it away like a bad ex, Brooks has done it all. As of 27 November 2025, the stock trades at ₹105, down 27% over the past year — because why not add emotional pain to financial statements?

With a market cap of ₹306 crore and a P/E of 21.9, Brooks looks modest until you notice its ROE of -12.2% and ROCE of -9.93%, which scream: “We made money, but accounting didn’t believe us.” Yet, the September 2025 quarter saw a PAT of ₹7.98 crore — a 302% jump YoY. For a company that was once a masterclass in losses, this feels like watching a student who finally passed maths after five attempts.

Sales came in at ₹23.45 crore, up 12.8% YoY. Promoter holding stands at 52.6%, with no pledges — a good sign that the management hasn’t yet mortgaged their hopes. Debt is a manageable ₹7.83 crore, and the current ratio of 1.73 says they can at least pay the bills. So yes, the comeback is real — but fragile, like a glass syringe.

2. Introduction

Pharma stocks often live on two things: patents and patience. Brooks Laboratories Ltd (BLL) runs on neither — it runs on pure resilience and caffeine. Incorporated in 2002, BLL manufactures and markets pharmaceutical formulations, specializing in contract manufacturing for critical care. Translation: they make the drugs that keep hospitals running while juggling client deadlines and cost inflation like a Bollywood stunt double.

From losing money till FY21 due to its Vadodara unit (which was bleeding faster than its own IV drips), Brooks found redemption by transferring that business to its joint venture, Brooks Steriscience Ltd. That move single-handedly saved the company’s financial health and ego. The turnaround was visible in FY22, when BLL posted a profit, but FY23 reminded everyone that API price volatility is a villain that never dies.

Now, FY25’s story is surprisingly upbeat. The company reported a consolidated PAT of ₹17.56 crore in H1 FY26, and even CARE upgraded its long-term credit rating to CARE BB (Stable). From a chronic struggler to a semi-stable operator — Brooks’ journey is every small investor’s favourite underdog plot.

3. Business Model – WTF Do They Even Do?

Brooks Laboratories is essentially the backstage crew of the pharmaceutical concert. They don’t own blockbuster drugs — they make sure other pharma players’ products get manufactured in time and within global compliance norms.

They produce liquid injections, dry powder injections, carbapenem injectables, tablets, and oral suspensions — the unsung heroes of ICUs and operation theatres. Their facilities at Baddi (Himachal Pradesh) boast a crazy production scale:

• 2.30 crore vials of liquid injections per annum
• 13.82 crore tablets
• 5.76 crore ampoules
• 5.19 crore dry powder injections
• 2.30 crore units for eye/ear drops

Essentially, if it’s injectable and life-saving, Brooks probably has a hand in it. Their products serve multiple therapeutic segments — antibacterials, antibiotics, anti-malarials, and antacids. And yes, they also bid on state government tenders, supplying drugs to Odisha, Rajasthan, Andhra Pradesh, and Kerala, besides exports to Yemen and Afghanistan.

So if you ever wondered who’s making the emergency medicine that saves lives in dusty district hospitals — meet Brooks Labs, the pharmaceutical Robin Hood (without the tights).

4. Financials Overview

Header Lock: Half Yearly Results – H1 FY2026

Let’s decode the financial potion they brewed this year:

The operating profit margin (OPM) finally turned positive after years of red ink, hitting double digits in the June–September stretch. PAT for Q2 FY26 alone was ₹7.98 crore — a stunning recovery from years of financial hangovers.

Brooks’ other income, however, remains the mysterious “supporting character” — ₹13.9 crore of it. Yes, it’s technically profit, but let’s just say it’s the kind of income that accountants call “non-core” and investors call “hope.”

5. Valuation Discussion – Fair Value Range Only

Method 1: P/E Multiple
With EPS (TTM) of ₹4.65 and